Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to heart failure with a focus on LVEF ≥ 40%. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated “October 10, 2024”.

Types of Enhancements Available

audio
Audio
infographic
Infographic
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 26    

Filtered results: 26

Effect of finerenone on the KCCQ in patients with HFmrEF/HFpEF: A prespecified analysis of FINEARTS-HF

Yang, M, et al. JACC. 2024;doi.org/10.1016/j.jacc.2024.09.023.

Yang M, 07 10 2024

Effects of the non-steroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure

Vaduganathan M, et al. Circulation. 2024;doi:10.1161/CIRCULATIONAHA.124.072055.

Vaduganathan M, 07 10 2024

Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced and preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial

Docherty KF, et al. Circulation. 2024;doi:10.1161/CIRCULATIONAHA.124.072011.

Docherty KF, 07 10 2024

Estimated long-term benefits of finerenone in heart failure: A prespecified secondary analysis of the FINEARTS-HF randomized clinical trial

Vaduganathan M, et al. J Am Coll Cardiol. 2024;doi:10.1001/jamacardio.2024.3782.

Vaduganathan M, 07 10 2024

Finerenone improves outcomes in patients with heart failure with mildly reduced or preserved ejection fraction irrespective of age: A prespecified analysis of FINEARTS-HF

Chimura M, et al. Circ Heart Fail. 2024;doi:10.1161/CIRCHEARTFAILURE.124.012437.

Chimura M, 07 10 2024

Finerenone in patients with a recent worsening heart failure event: The FINEARTS-HF trial

Desai AS, et al. J Am Coll Cardiol. 2024; S0735-1097(24)08452-3.

Desai AS, 07 10 2024

Time to significant benefit of finerenone in patients with heart failure

Vaduganathan M, et al. J Am Coll Cardiol. 2024;S0735-1097(24)08512-7.

Vaduganathan M, 07 10 2024

Finerenone in heart failure and chronic kidney disease with type 2 diabetes: The FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes

Vaduganathan M, et al. Nat Med. 2024;doi:10.1038/s41591-024-03264-4

Vaduganathan M, 01 09 2024

Finerenone in heart failure with mildly reduced or preserved ejection fraction

Solomon SD, et al. N Engl J Med. 2024;doi:10.1056/NEJMoa2407107

Solomon SD, 01 09 2024

Mineralocorticoid receptor antagonists in heart failure: An individual patient level meta-analysis

Jhund PS, et al. Lancet. 2024;doi:10.1016/S0140-6736(24)01733-1

Jhund PS, 01 09 2024